Merck, Roche, BMS impress at ASCO, but questions linger
This article was originally published in Scrip
Experimental cancer-fighting drugs from Roche, Bristol-Myers Squibb and Merck & Co. lived up to their advanced billings at a major medical meeting over the weekend, but the impressive data also raised questions about the next steps forward.
You may also be interested in...
Using Baxter’s Advate drug as a preventative therapy helped significantly reduce bleeding incidents in a yearlong study.
Mylan CEO Heather Bresch said she is looking to do a sizable deal that helps the US generic and specialty drug maker better compete in a consolidating field of rivals.
Biogen Idec CEO George Scangos is frank about his ambitions to dominate the market for hemophilia therapies, an opportunity he compares to the big biotech’s lead treating multiple sclerosis.